


The power of *in vivo* preclinical imaging and prospect clinical applications



J. Arturo GarcíaHorsman
Head of Real-time Imaging Laboratory
University of Helsinki

Potential partner in upcoming H2020 calls in



SC1BHC012019: Understanding causative mechanisms in co/multimorbidities combining mental and non-mental disorders

SC1BHC082020: New interventions for NonCommunicable Diseases

SC1BHC272018: New testing and screening methods to identify endocrine disrupting chemicals

DEVELOPING OF NEW NONINVASIVE BIOMARKERS FOR DISEASE

Unilateral
Parkinson's
rat model



Validation of a
**NEW BIOMARKER FOR
NEUROINFLAMMATION**

If you are interested in:

- Validate a drug target
- Validate a drug delivery system
- Quantify a receptor/enzyme
- Verify neurotransmission capacity
- Verify therapy efficacy in animal models
- Determine disposition routes
- Authenticate pharmacodynamics/kinetics
- etc...

And doing it

in vivo, free of post-mortem artefacts, longitudinally, statistically cheap,
and ethically convenient


Then you need **SPECT/CT**

The Helsinki nanoSPECT/CT imaging laboratory

provides a key technology in several successful research projects

- Academy of Finland: Radiotracers for imaging in drug delivery. *Airaksinen 2010-2016.*
- Finnish Technology agency : 3iRegeneration – targeted drug-delivery to heart and brain using nano-carriers *Ruskoaho, Santos, Tuominen 2014 – 2017.*
- ERC starting grant and Academy of Finland: Nanoparticles for targeted imaging cancer therapy. *Santos, 2011 – 2017.*
- ERC consolidator grant: Cancer immunotherapy *Cerullo 2015 – 2020.*
- Academy of Finland: Nanoparticle assisted brain imaging. *Bergström 2012-2016.*
- IMI: COMPACT Collaboration on the optimization of macromolecular pharmaceutical access to cellular targets. *Urtti 2013 – 2017.*





Thank
you!!

nanoSPECT/CT Helsinki